Danish pharmaceutical major Novo Nordisk launched its once-weekly basal insulin injection, Awiqli, in India for the treatment of diabetes in adults, marking the country's entry as the seventh market to introduce the therapy.

Here are some interesting facts of Awiqli

1. Awiqli is a prescription medicine and is the first and only FDA-approved once-weekly basal insulin indicated as an adjunct to diet and exercise for adults with type 2 diabetes.

2. It is designed as an alternative to daily basal insulin and its approval is supported by the ONWARDS clinical program, which evaluated its efficacy and safety across diverse adult populations living with type 2 diabetes

3. It is pronounced “ah-WIK-lee."

4. It was approved by the FDA on March 26, 2026

5. As per reports, the injection will be introduced in two pens - 700 units and 2,100 units, with a per unit cost of Rs. 3.73.

6. It is not known if Awiqli is safe and effective in children and adolescents

7. As per reports, Awiqli should not be taken if you are having an episode of low blood sugar or having allergic infections

Northeast Now

[{"selector":"#anim-a54b9844-3250-4ae0-8284-a3769115b95b","keyframes":{"opacity":[0,1]},"delay":0,"duration":1600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-6c87e7ec-431e-444d-9ba3-da301ef2e621","keyframes":{"transform":["translate3d(0px, 94.42019%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":1600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-2fdbe80a-4157-4129-bd6a-df559291743f","keyframes":{"opacity":[0,1]},"delay":300,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-529527c2-6c00-45d8-9143-5b22bade9d5a","keyframes":{"transform":["translate3d(0px, 824.90368%, 0)","translate3d(0px, 0px, 0)"]},"delay":300,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-fe730142-837a-4f15-9173-bc9a02901896","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-b38b251b-df5b-406d-936c-215d47d5ce69","keyframes":{"transform":["translate3d(0px, 454.20090%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-871469c4-a71e-43b2-91c4-8c439941bd22","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-99f0e4cc-c5a7-4d79-82d1-fce993cb644e","keyframes":{"transform":["translate3d(0px, 295.66420%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] www.nenow.in

Danish pharmaceutical major Novo Nordisk launched its once-weekly basal insulin injection, Awiqli, in India for the treatment of diabetes in adults, marking the country's entry as the seventh market to introduce the therapy.

Danish pharmaceutical major Novo Nordisk launched its once-weekly basal insulin injection, Awiqli, in India for the treatment of diabetes in adults, marking the country's entry as the seventh market to introduce the therapy.

Here are some interesting facts of Awiqli

Here are some interesting facts of Awiqli

1. Awiqli is a prescription medicine and is the first and only FDA-approved once-weekly basal insulin indicated as an adjunct to diet and exercise for adults with type 2 diabetes.

1. Awiqli is a prescription medicine and is the first and only FDA-approved once-weekly basal insulin indicated as an adjunct to diet and exercise for adults with type 2 diabetes.

2. It is designed as an alternative to daily basal insulin and its approval is supported by the ONWARDS clinical program, which evaluated its efficacy and safety across diverse adult populations living with type 2 diabetes

2. It is designed as an alternative to daily basal insulin and its approval is supported by the ONWARDS clinical program, which evaluated its efficacy and safety across diverse adult populations living with type 2 diabetes

3. It is pronounced “ah-WIK-lee."

3. It is pronounced “ah-WIK-lee."

4. It was approved by the FDA on March 26, 2026

4. It was approved by the FDA on March 26, 2026

5. As per reports, the injection will be introduced in two pens - 700 units and 2,100 units, with a per unit cost of Rs. 3.73.

5. As per reports, the injection will be introduced in two pens - 700 units and 2,100 units, with a per unit cost of Rs. 3.73.

6. It is not known if Awiqli is safe and effective in children and adolescents

6. It is not known if Awiqli is safe and effective in children and adolescents

7. As per reports, Awiqli should not be taken if you are having an episode of low blood sugar or having allergic infections

7. As per reports, Awiqli should not be taken if you are having an episode of low blood sugar or having allergic infections

Northeast Now

Read More

Click Here